Background {#Sec1}
==========

Allergen inhalation challenge is a valuable research tool for the study of asthma pathophysiology and investigational new drug efficacy \[[@CR1]\]. The early asthmatic response (EAR) to allergen depends on (non-allergic) airway responsiveness and the level of allergen-specific IgE \[[@CR2]\]. It has been previously demonstrated that the concentration/dose of allergen required to produce a threshold EAR of a 20% decline in forced expired volume in one second (FEV~1~) can be predicted within 2--3 concentrations using the level of airway responsiveness measured by methacholine or histamine provocation and the level of allergen specific IgE assessed by the allergen skin test endpoint titration (STE) \[[@CR3]\]. A caveat for this prediction is the requirement for methacholine and allergen to be inhaled in the same fashion using the same type of nebulizer, calibrated to the same weight loss.

Historically, the Wright^®^ jet nebulizer (Roxon Medi-Tech, St. Leonard, QC) calibrated to run at a weight loss of 0.13 g/min with inhalation performed by two minutes of tidal breathing \[[@CR4]\] has been used for both methacholine and allergen inhalation. The Wright^®^ nebulizer is inefficient (approximately 75% of weight loss is evaporation \[[@CR5], [@CR6]\]), expensive, non-disposable, and increasingly difficult to acquire. The Aerogen Solo^®^ vibrating mesh nebulizer, referred to as the Solo^®^ throughout, (Aerogen Ltd, Galway Ireland) features no evaporation and has been validated for use in methacholine challenge testing \[[@CR7], [@CR8]\]. The current study was designed to assess the Solo^®^ vibrating mesh nebulizer for use in the standardized allergen challenge protocol performed in AllerGen National Centres of Excellence (NCE) Clinical Investigator Collaborative (CIC) studies and to compare it to the current Wright^®^ jet nebulizer protocol.

Methods {#Sec2}
=======

Participants {#Sec3}
------------

Eligible participants had mild atopic asthma requiring only infrequent inhaled β~2~ agonist, an FEV~1~ \> 70% predicted, and a methacholine provocation dose causing a 20% fall in FEV~1~ (PD~20~) ≤ 400 μg. Participants were non-smokers with \< 10 pack year cumulative smoking history. Individuals who were pregnant, lactating, who had relevant allergen exposure or respiratory tract infection within the previous 4 weeks or who had significant medical conditions were excluded. Ethics approval was received from each study site and signed informed consent was obtained prior to study entry.

Study design {#Sec4}
------------

Participants attended the laboratory on 5 occasions. Visit 1 visit was to assess eligibility, to obtain signed consent, to perform baseline spirometry and screening allergen skin prick tests and from these select the best allergen for inhalation testing. The selected allergen was one which was clinically relevant to the participant and which produced a large (≥ 5 mm) wheal. The STE for the selected allergen was measured at Visit 2 to allow prediction of the starting allergen concentration for inhalation in conjunction with the methacholine response \[[@CR3]\]. At Visits 2 and 3 the methacholine PD~20~ and the allergen PD~20~ were measured respectively both with either the Wright^®^ or the Solo^®^ nebulizer. After a minimum 2-week washout, at Visits 4 and 5 these challenges were repeated with the other nebulizer. The order of the nebulizers was randomized.

Skin test endpoint (STE) titration {#Sec5}
----------------------------------

The STE was determined as previously outlined \[[@CR9]\]. Allergens (Omega Laboratories, Montreal QC) were dispensed in protein nitrogen units/mL, biologic allergen units/mL or allergen units/mL. For conformity the allergen dose was expressed in "units". Allergens were diluted two-fold from 1:8 to 1:1024 or beyond if required and the dilutions were labeled as the allergen concentration in units/mL. Duplicate skin prick tests were performed, the mean wheal diameter measured at 10 min, and the STE recorded as the weakest concentration (units/mL) causing a 2 mm mean wheal diameter.

Methacholine inhalation tests {#Sec6}
-----------------------------

The standard Wright^®^ nebulizer methacholine test \[[@CR4], [@CR10]\] was done as follows. The nebulizer was calibrated to a weight loss of 0.13 g/min. Complete spirometry was initially measured in triplicate. Isotonic saline was then inhaled by tidal breathing for 2 min, and the FEV~1~ (truncated manoeuvre to avoid fatigue) measured at 30 and 90 s. Doubling concentrations of methacholine were then inhaled in the same manner at 5 min intervals with FEV~1~ repeated at 30 and 90 s The available concentrations ranged from 0.031 to 64 mg/mL; the starting concentration for an individual was selected based on previous testing if available or based on validated guidelines \[[@CR10], [@CR11]\]. Inhalations were stopped when the FEV~1~ had fallen ≥ 17% and the provocation concentration causing a 20% FEV~1~ fall (PC~20~) was interpolated from the last 2 data points \[[@CR10]\] or extrapolated from the last data point \[[@CR12]\]. The PC~20~ was converted to a PD~20~ (μg) based on several studies documenting that a Wright^®^ PC~20~ of 16 mg/mL equates to a PD~20~ of 400 μg \[[@CR6]--[@CR8], [@CR13], [@CR14]\]. The accepted values for a normal (negative) methacholine challenge test are PC~20~ and PD~20~ \> 16 mg/mL and \> 400 μg respectively \[[@CR15]\].

The Solo^®^ methacholine challenge was done as previously described \[[@CR8]\]. Doubling doses of methacholine were delivered by nebulizing 0.5 mL of methacholine to completion and inhaling by tidal breathing; this requires 90 to 180 s \[[@CR8]\]. A concentration of 2 mg/mL × 0.5 mL × 0.4 (respiratory duty cycle \[[@CR16]\]) exposes the individual to 400 μg. Following saline inhalation appropriate doubling concentrations up to 4 mg/mL (= 800 μg) were used. The remainder of the challenge (timing of FEV~1~ measurements, time between doses, calculation of the PD~20~, etc.) was identical to the Wright^®^ method.

Allergen inhalation tests {#Sec7}
-------------------------

Allergen inhalation tests were done as previously described using the Wright^®^ nebulizer \[[@CR17]\]. Spirometry was measured in triplicate. Doubling concentrations of allergen were then inhaled (2 min of tidal breathing, nebulizer calibrated to a weight loss of 0.13 g/min and starting 3 or 4 concentrations below the predicted EAR concentration \[[@CR3]\]) at 12 min intervals until the FEV~1~ measured at 10 min after inhalation had fallen ≥ 15%. At an FEV~1~ fall between 15 and 20% the FEV~1~ was repeated 10 min later before giving another concentration if required. The allergen PC~20~ (units/mL) was converted to allergen PD~20~ (units) assuming a similar relationship as seen with methacholine. After PD~20~ measurement, participants received a single inhaled dose of salbutamol 200 μg to reverse bronchoconstriction and a single inhaled dose of fluticasone propionate 500 μg to prevent development of the late asthmatic response \[[@CR18]\].

The Solo^®^ allergen challenge was performed in an analogous manner. Assuming a similar relationship for dose comparison between the Solo^®^ and the Wright^®^ nebulizers seen with methacholine, the starting allergen concentration was 3 doubling concentrations below the starting concentration used for the Wright^®^ (i.e. 6--7 concentrations below the Wright^®^ prediction). The allergen, 0.5 mL, was nebulized to completion and inhaled by tidal breathing; the remainder of the challenge protocol was identical to the Wright^®^ protocol; the result was expressed as the allergen PD~20~ in units.

Analysis {#Sec8}
--------

Statistics were done using a computerized statistics programme (Statistix 9 (Analytical Software, Tallahassee, FL, USA). PD~20~ and STE values were log transformed prior to analysis. The Student's paired t test was used for comparison of means. Linear regression analysis was used for the following (all values logged):Measured Wright^®^ allergen PD~20~ vs Predicted allergen PD~20.~Wright^®^ allergen PD~20~ vs Wright^®^ methacholine PD~20.~Wright^®^ allergen PD~20~ vs STE.Wright^®^ allergen PD~20~ vs (Wright^®^ methacholine PD~20~ × STE).Measured Solo^®^ allergen PD~20~ vs Predicted allergen PD~20.~Solo^®^ allergen PD~20~ vs Solo^®^ methacholine PD~20.~Solo^®^ allergen PD~20~ vs STE.Solo^®^ allergen PD~20~ vs (Solo^®^ methacholine PD~20~ × STE).

Results {#Sec9}
=======

Eighteen participants, all poylsensitized but with no current allergen exposure (except house dust mite), completed the study without adverse events. Three additional enrolled participants did not complete the study; one because the FEV~1~ was \< 70% at Visit 1, one because the methacholine PD~20~ was \> 400 μg at Visit 2, and one because of a failure to respond to allergen (1:32 with the Solo^®^ equating to \~ 1:4 with the Wright^®^) at Visit 3. Anthropometric data, baseline FEV~1~, baseline methacholine PD~20~ and allergen used for challenges are shown in Table [1](#Tab1){ref-type="table"}.Table 1Demographics, FEV~1~, methacholine PD~20~, and allergen used for inhalationParticipantSite^a^SexAge (year)Height (cm)Weight (kg)FEV~1~ (L)FEV~1~ (%)Methacholine PD20 (μg)Allergen1SM4217886.43.508429.1Cat2SM2417081.84.159882.7Cat3SF2517070.93.539855.4Cat4SM2717079.53.608781.5Cat5SF2316248.62.6882118Mite6SF4215854.52.499010.5Mite7LM4217367.93.4488171Birch8LF3016266.93.66115239Cat9LM3518263.13.7882142Cat10LF3815777.62.61928.9Cat11LF2515283.03.161121.9Cat12LM3418673.23.668826.6Horse13MM58184102.03.6992162Mite14MM5417576.03.409580.6Cat15MM2818187.94.579818.1Grass16MF2117472.53.088246.5Grass17MF2516169.52.5078265Ragweed18MF3016780.03.3610129.4MiteMean33.5170.174.53.3892.349.3^b^SD10.710.012.40.5510.1(25.8--94.0)^a^Site: S = Saskatchewan, L = Laval, M = McMaster^b^Geometric mean (95% confidence intervals)

Wright^®^ {#Sec10}
---------

The measured allergen PD~20~ correlated with the predicted allergen PD~20~ (r = 0.91, p \< 0.00001) and all predictions were within 2 (maximum 1.96) doubling doses of the measured allergen PD~20~ (Fig. [1](#Fig1){ref-type="fig"}). The geometric means for the measured and predicted PD~20~ values were 6.7 units (95% CI 2.7--15.8) and 7.0 units (95% CI 2.5--17.7) respectively (p = 0.68). The allergen PD~20~ (units) correlated with both the methacholine PD~20~ (r = 0.74) and the STE (r = 0.78,). Allergen PD~20~ correlated more strongly with the product of the methacholine PD~20~ (μg) and the STE (units/mL) (r = 0.91, p \< 0.00001) (Fig. [2](#Fig2){ref-type="fig"}).Fig. 1Measured Wright^®^ allergen PD~20~ (units) on the vertical axis and predicted allergen PD~20~ (units) on the horizontal axis both plotted in a log scale. The solid line is the line of identity and the dashed lines represent ± 2 doubling doses Fig. 2Wright^®^ allergen PD~20~ on the vertical axis and Wright^®^ Methacholine PD~20~ × STE on the horizontal axis both plotted on a log scale. The regression equation is; Log Allergen PD~20~ (units) = − 1.03 + 0.64 × log (Methacholine PD~20~ \[μg\] × STE \[units/mL\])

Solo^®^ {#Sec11}
-------

The measured Solo^®^ allergen PD~20~ correlated with the predicted allergen PD~20~ (r = 0.84, p = 0.000013) and was within 2 doubling does of the predicted allergen PD~20~ in 14 of 18 and within 2.64 doubling doses in all 18 (Fig. [3](#Fig3){ref-type="fig"}). Similar to the Wright^®^, the Solo^®^ allergen PD~20~ correlated with both the Solo^®^ methacholine PD~20~ (r = 0.61) and the STE (r = 0.75) and more strongly with the product of the 2 (r = 0.83, p = 0.00002) (Fig. [4](#Fig4){ref-type="fig"}).Fig. 3Measured Solo^®^ allergen PD~20~ (units) on the vertical axis and predicted allergen PD~20~ (units) on the horizontal axis both plotted in a log scale. The solid line is the line of identity, the dashed lines represent ± 2 doubling doses and the dotted lines ± 2.64 doubling doses Fig. 4Solo^®^ allergen PD~20~ on the vertical axis and Solo^®^ Methacholine PD~20~ × STE on the horizontal axis plotted on a log scale. The regression equation is; Log Allergen PD~20~ (units) = − 0.62 + 0.56 × log (Methacholine PD~20~ \[μg\] × STE \[units/mL\])

Wright^®^ Solo^®^ comparisons {#Sec12}
-----------------------------

The Wright^®^ and the Solo^®^ methacholine PD~20~s were not significantly different with geometric means of 49.3 (95% CI 25.8--94.0) and 54.2 μg (95% CI 26.7--110) respectively (p = 0.62). The geometric mean Wright^®^ allergen PD~20~, 6.7 units (95% CI 2.7--15.8), was slightly but significantly lower than geometric mean Solo^®^ allergen PD~20~, 10.5 units (95% CI 4.4--25.1), (p = 0.003). Individual values for the Wright^®^ and the Solo^®^ allergen PD~20~s are shown in Fig. [5](#Fig5){ref-type="fig"}. There was no sequence effect (i.e. nebulizer order) nor was there any difference between the three sites.Fig. 5Individual values for Wright^®^ allergen PD~20~ on the left and Solo^®^ allergen PD~20~ on the right. The red points are the geometric means with standard error bars. The Wright^®^ allergen PD~20~ is slightly but significantly smaller than the Solo^®^ allergen PD~20~ (6.7 vs 10.5 units respectively, p = 0.003)

Discussion {#Sec13}
==========

These data indicate that the Solo^®^ vibrating mesh nebulizer can be successfully used for performance of allergen inhalation tests. Allergen responsiveness showed the same relationship with methacholine responsiveness and level of allergen sensitivity as was seen with the Wright^®^ nebulizer protocol. The measured Solo^®^ allergen PD~20~ was within 2.64 doubling doses of the prediction.

In 1987, an equation was developed to predict the dilution/concentration of allergen that would produce a 20% EAR \[[@CR3]\]. This was based on the histamine PC~20~ (mg/mL) and the allergen skin test endpoint (dilution) producing a 2 mm wheal. Both allergen and histamine were inhaled with 2 min of tidal breathing from a Wright^®^ nebulizer calibrated in the same manner. Methacholine was subsequently substituted for histamine in the same concentration since histamine and methacholine PC~20~s are identical in asthmatics \[[@CR19]\]. In the original study, the equation successfully estimated the dilution required for an EAR within 2 doubling dilutions in 92% and 3 doubling dilutions in 100% of challenges \[[@CR3]\]. The equation and a sample calculation are below:$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$${\text{Log}}\;{\text{predicted}}\;{\text{allergen}}\;{\text{dilution}}\, = \,0.68\log \left( {{\text{methacholine}}\;{\text{PC}}_{20} \, \times \,{\text{STE}}\;{\text{dilution}}} \right)$$\end{document}$$

For example with a methacholine PC~20~ of 2.2 mg/mL and an STE of 1/1024.$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$${\text{Log}}\;{\text{predicted}}\;{\text{allergen}}\;{\text{dilution}}\, = \,0.68\log \left( {2.2\, \times \,1/1024} \right)\, = \, - 1.81$$\end{document}$$ $$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$${\text{Predicted}}\;{\text{allergen}}\;{\text{dilution}}\, = \,{\text{antilog}}\left( { - 1.81} \right)\, = \,0.0155\,\sim \,1/64\;{\text{dilution}}.$$\end{document}$$

This prediction is routinely used as a guide for allergen challenge tests. A starting allergen dilution of 3 or occasionally 4 doubling dilutions below the prediction has proved a safe and effective method for allergen challenges performed in AllerGen NCE CIC and other studies. The purpose is to allow some test shortening when compared to methods advocating starting with the weakest allergen dilution causing a 2 mm wheal skin test response \[[@CR20]\]. The current study validates this prediction equation when applied to the Wright^®^ data, since all measured values were within 2 doubling doses of the prediction. Despite the slightly higher measured Solo^®^ allergen PD~20~ vs the Wright^®^ (i.e. slightly *less* responsive), 78% of values were within 2 doubling doses and 100% within 2.64 doubling doses. This would suggest that the 1987 prediction equation can be safely and effectively used (with modification for the units and nebulizer differences) until such time as there are enough data to develop a "Solo^®^ specific" equation.

The major strength of this study is the experienced group of investigators at the three sites. The one weakness is the inability to assess the solute output of the jet (Wright®) nebulizer. Based on the known evaporative features \[[@CR5], [@CR6]\], and both breath simulation testing \[[@CR6]\] and clinical challenge testing \[[@CR7], [@CR8], [@CR12], [@CR13]\] it is reasonable to equate a methacholine PC~20~ of 16 mg/mL to a methacholine PD~20~ of 400 μg. The current study validates this, since using this conversion the Wright^®^ and Solo^®^ methacholine PD~20~s were essentially identical. However, data are currently lacking for nebulized allergen and it is possible that allergen solutions could be handled differently by the nebulizers.

Conclusion {#Sec14}
==========

In summary the Solo^®^ vibrating mesh nebulizer, proved to be a safe, effective and well tolerated device for administering inhaled allergen. This provides a valuable alternative to the Wright^®^ jet nebulizer.

STE

:   skin (prick) test endpoint

FEV~1~

:   forced expired volume in one second

PC~20~

:   provocation concentration causing a 20% FEV~1~ fall

PD~20~

:   provocation dose causing a 20% FEV~1~ fall

EAR

:   early asthmatic response

SD

:   standard deviation

CI

:   confidence interval

NCE

:   National Centres of Excellence

CIC

:   Clinical Investigator Collaborative

**Publisher\'s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The authors thank Jacquie Bramley for assistance in preparation of the manuscript and Aerogen Ltd for supplying the Solo^®^ nebulizers.

Study design and protocol development: BED, CMB, DWC, GMG, PMO, LPB; Data collection: BED, CMB, DWC, LPB, MEB, GMG, HV, KJH, CDO; data analysis: DWC, CMB, BED; Manuscript preparation: DWC, BED, CMB; manuscript approval. All authors read and approved the final manuscript.

This study was funded by a grant form AllerGen NCE. AllerGen had no role in study design, data collection analysis or interpretation, or in the writing of the manuscript. CMB received a summer student support grant from the CSACI

All data are available from the corresponding author on reasonable request don.cockcroft\@usask.ca.

Ethics approval was obtained from each site and signed informed consent was obtained from each participant.

We consent to publication of this paper.

The authors declare that they have no competing interests.
